TITLE

High concentrations of GRO-α and MCP-1 in bronchoalveolar fluid of infants with respiratory distress syndrome after surfactant

AUTHOR(S)
Inwald, David P.; Costeloe, Kate; Murch, Simon H
PUB. DATE
May 1998
SOURCE
Archives of Disease in Childhood -- Fetal & Neonatal Edition;May1998, Vol. 78 Issue 3, p234
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
67245697

 

Related Articles

  • Temple speaks out on ethical issues with pediatric trial. Dickinson, James G. // Medical Marketing & Media;Apr2001, Vol. 36 Issue 4, p32 

    Focuses on the ethical implications of conducting the placebo-control trial of surfactants in Latin America. High mortality rate of premature newborn infants; Treatment of the respiratory distress syndrome in premature neonates; Availability of marketed surfactants in the country.

  • Preterm babies get a double breath of life. Williams, R.D. // FDA Consumer;Apr92, Vol. 26 Issue 3, p10 

    Announces that respiratory distress syndrome (RDS) in infants is now more treatable through the use of pulmonary surfactants. Infant deaths significantly reduced; Risks among premature babies; Use of high-frequency ventilators; Future prospects.

  • Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. Markart, Philipp; Ruppert, Clemens; Wygrecka, Malgorzata; Colaris, Thorsten; Dahal, Bhola; Walmrath, Dieter; Harbach, Heinz; Wilhelm, Jochen; Seeger, Werner; Schmidt, Reinhold; Guenther, Andreas // Thorax;Jul2007, Vol. 62 Issue 7, p588 

    Background: Extensive biochemical and biophysical changes of the pulmonary surfactant system occur in the acute respiratory distress syndrome (ARDS). Methods: The effect of intrabronchial administration of a recombinant surfactant protein C-based surfactant preparation (Venticute) on gas...

  • Is there really a clinical difference in surfactant preparations? Fujii, Alan // Journal of Perinatology;Oct2010, Vol. 30 Issue 10, p698 

    A letter to the editor is presented in response to the article on the use of a particular surfactant in the management of very premature infants with respiratory distress syndrome.

  • Uso de surfactante pulmonar exógeno en el neonato pretérmino con Síndrome de Dificultad Respiratoria, Estrategia de Rescate. Experiencia del Instituto Nacional de Perinatología 1997-1998. Salinas Ramiírez, Vicente; Angel Gúzman Reyes, Lidio; Mórales Suárez, Moises; Hernández Pelaez, Graciela; Yllescas Medrano, Eucario; Albert Zapata Pallagi, James // Perinatologia y Reproduccion Humana;oct-dic1999, Vol. 13 Issue 4, p286 

    KEY WORDS: [Surfactant pulmonary exogenous, preterm infants, neonatal respiratory distress syndrome, hyaline membrane disease.]

  • Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. Amizuka, Takasuke; Shimizu, Hiroshi; Niida, Yuichi; Ogawa, Yunosuke // European Journal of Pediatrics;2003, Vol. 162 Issue 10, p697 

    Unlabelled: We studied the clinical and biochemical factors associated with surfactant dysfunction and factors affecting the responsiveness to exogenous surfactant among 27 neonates with haemorrhagic pulmonary oedema (HPE). HPE was defined as the presence of a large amount of...

  • Nasal intermittent positive pressure ventilation after surfactant treatment for respiratory distress syndrome in preterm infants <30 weeks' gestation: a randomized, controlled trial. Ramanathan, R; Sekar, K C; Rasmussen, M; Bhatia, J; Soll, R F // Journal of Perinatology;May2012, Vol. 32 Issue 5, p395 

    A correction to the article "Nasal intermittent positive pressure ventilation after surfactant treatment for respiratory distress syndrome in preterm infants <30 weeks' gestation: a randomized, controlled trial" in a previous issue is presented.

  • Surfaxin to Prevent RDS.  // Monthly Prescribing Reference;May2012, Vol. 28 Issue 5, pA-8 

    The article offers information that Surfaxin, a peptide surfactant, from Discovery Laboratories Inc. has been approved for prevention of high-risk premature infants with respiratory distress syndrome (RDS).

  • Respiratory Distress in the Newborn. Hermansen, Christian L.; Lorah, Kevin N. // American Family Physician;10/1/2007, Vol. 76 Issue 7, p987 

    The most common etiology of neonatal respiratory distress is transient tachypnea of the newborn; this is triggered by excessive lung fluid, and symptoms usually resolve spontaneously. Respiratory distress syndrome can occur in premature infants as a result of surfactant deficiency and...

  • BOX 15-2 HYALINE MEMBRANE DISEASE. Scanlon, Valerie C.; Sanders, Tina // Essentials of Anatomy & Physiology;Jan2007, p351 

    Information on hyaline membrane disease from Chapter 15 of the book "Essentials of Anatomy & Physiology," is presented. The disease, which is also called respiratory distress syndrome, often affects premature infants whose lungs have not yet produced sufficient quantities of pulmonary...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics